IP Library Granted Patent US 7,947,823
Granted Patent B2
US 7,947,823 · App. 10/564,020 · Granted May 24, 2011

siRNA expression system

Assignee: Universita degli Studi di Roma “La Sapienza”
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,947,823
App. No.
10/564,020
Granted
May 24, 2011
Kind
B2
Abstract

The authors describe an expression system for the correct, stable and effective expression in mammalian cells of a siRNA comprising: a) a polymerase II RNA-dependent promoter derived from the U1 RNA gene; downstream from the sequence b) suitable restriction sites for the cloning of the sequence transcribing the pre-siRNA; downstream from these sites c) sequences derived from the sequences at 3′ of the gene for U1 snRNA that are necessary and sufficient for the correct formation of 3′ of the presiRNA.

Claims (31)

1. A recombinant vector for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA, comprising from 5′ to 3′:

a) an RNA polymerse II dependent promoter sequence derived from the U1 snRNA gene;

b) suitable restriction sites for cloning the sequence that transcribes a presiRNA or a pre-miRNA;

c) a sequence transcribing the pre-siRNA or pre-miRNA comprising: in position +1 an A or a G residue; a sequence from 21 to 23 nucleotides corresponding to a sense region of the mRNA transcribed by the gene to be silenced; a sequence selected to form a loop region; a sequence from 21 to 23 nucleotides corresponding to the antisense region of the mRNA transcribed by the gene to be silenced; wherein the residues at the 3′ end protrude in such a way that the following structure is obtained:

wherein Y is optionally present, and X and Y if Y is present are independently one or more nucleotides, wherein the nucleotides at the 3′ end are selected to result in asymmetry in siRNA or miRNA strand selection into an interference complex; and

d) termination sequences derived from the sequence at 3′ of the gene for U1 snRNA which are necessary and sufficient for the correct formation of the 3′ of the pre-siRNA or of the pre- miRNA, wherein the recombinant vector provides for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA.

2. The vector according to claim 1 , wherein the restriction site for cloning at the 5′ end of the sequence transcribing the pre-siRNA is BglII .

3. A recombinant vector for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA, comprising from 5′ to 3′:

a) an RNA polymerse II dependent promoter sequence derived from the U1 snRNA gene;

b) suitable restriction sites for cloning the sequence that transcribes a presiRNA or a pre- miRNA;

c) a sequence transcribing the pre-siRNA or the pre-miRNA comprising: in positions +1 an A or a G residue; a sequence from 21 to 23 nucleotides corresponding to a sense region of the mRNA transcribed by the gene to be silenced; a sequence selected to form a loop region; a sequence selected from 21 to 23 nucleotides corresponding to the antisense region of the mRNA transcribed by the gene to be silenced; wherein the residues at the 3′ end protrude in such a way that the following structure is obtained:

wherein each N is independently A, U, G or C and N′ is its complementary nucleotide, wherein Y is optionally present, wherein X and Y if Y is present are independently one or more nucleotides, wherein the nucleotides at the 3′ end are selected to result in asymmetry in siRNA or miRNA strand selection into an interference complex; and

d) termination sequences derived from the sequence at 3′ of the gene for U1 snRNA which are necessary and sufficient for the correct formation of the 3′ of the pre-siRNA or of the pre-miRNA, wherein the recombinant vector provides for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA.

4. A recombinant vector for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA, comprising from 5′ to 3′:

a) an RNA polymerse II dependent promoter sequence derived from the U1 snRNA gene;

b) suitable restriction sites for cloning the sequence that transcribes a presiRNA or a pre- miRNA;

c) a sequence transcribing the pre-siRNA or the pre-miRNA comprising: in position +1 an A or a G residue; a sequence from 21 to 23 nucleotides corresponding to a sense region of the mRNA transcribed by the gene to be silenced; a sequence selected to form a loop region; a sequence from 21 to 23 nucleotides corresponding to the antisense region of the mRNA transcribed by the gene to be silenced that constitutes the second segment of the stem of the pre-siRNA; wherein the residues at the 3′ end protrude in such a way that the following structure is obtained:

and

d) termination sequences derived from the sequence at 3′ of the gene for U1 snRNA which are necessary and sufficient for the correct formation of the 3′ of the pre-siRNA or of the pre-miRNA, wherein the recombinant vector provides for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA.

5. The vector according to claim 4 wherein the termination sequences derived from the sequence at 3′ of the gene for U1 snRNA are as follows:

CCCCTG/ACTTTCTGGAGTTTCAAAAGTAGAC.

(SEQ ID NO:18)

6. The vector according any of claims 1 to 5 further comprising suitable sequences to make inducible the RNA pol II promoter.

7. A recombinant vector for the correct, stable and effective expression in mammalian cells of a siRNA or a miRNA, comprising from 5′ to 3′:

a) an RNA polymerse II dependent promoter sequence derived from the U1 snRNA gene;

b) suitable restriction sites for cloning the sequence that transcribes a presiRNA or a pre- miRNA;

c) a sequence transcribing the pre-siRNA comprising: in position +1 an A or a G residue; a sequence from 21 to 23 nucleotides corresponding to a sense region of the mRNA transcribed by the gene to be silenced; a sequence selected to form a loop region; a sequence from 21 to 23 nucleotides corresponding to the antisense region of the mRNA transcribed by the gene to be silenced; wherein one of the following structures is obtained:

wherein each N is independently A, U, G or C and N′ is its complementary nucleotide, wherein Y is optionally present, wherein X and Y if Y is present are independently one or more nucleotides, wherein the nucleotides at the 3′ end are selected to result in asymmetry in siRNA strand selection into an interference complex, or

or alternatively a sequence transcribing the pre-miRNA; and

d) termination sequences derived from the sequence at 3′ of the gene for U1 snRNA which are necessary and sufficient for the correct formation of the 3′ of the pre-siRNA or of the pre-miRNA.

8. A composition for gene therapy comprising the vector according to claim 1 , 3 , 4 or 7 .

Assignments (3)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2007
From: BOZZONI, IRENE; DENTI, MICHELA ALESSANDRA; ROSA, ALESSANDRO
To: UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA"
Reel/Frame 019596/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2006
From: BOZZONI, IRENE; DENTI, MICHELA ALESSANDRA
To: UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA"
Reel/Frame 017467/0159 →
Priority Claims (1)
IT RM2003A0335 · Jul 9, 2003 · national
Continuity (1)
Related Publication 20060217327A1 · Sep 28, 2006